Xenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Xenon Pharmaceuticals (NASDAQ:XENE) posted its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.09, Morningstar.com reports.

XENE traded down $0.24 during trading on Friday, hitting $9.24. The company had a trading volume of 9,412 shares, compared to its average volume of 41,772. The company has a market cap of $244.30 million, a P/E ratio of -6.95 and a beta of 1.33. The stock has a 50-day moving average of $9.78. The company has a current ratio of 17.57, a quick ratio of 17.57 and a debt-to-equity ratio of 0.18. Xenon Pharmaceuticals has a 1-year low of $5.41 and a 1-year high of $15.92.

A number of hedge funds have recently added to or reduced their stakes in XENE. Northern Trust Corp increased its stake in Xenon Pharmaceuticals by 18.9% during the fourth quarter. Northern Trust Corp now owns 12,246 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 1,948 shares during the last quarter. Geode Capital Management LLC bought a new stake in Xenon Pharmaceuticals during the fourth quarter valued at $88,000. Two Sigma Advisers LP bought a new stake in Xenon Pharmaceuticals during the fourth quarter valued at $228,000. Falcon Point Capital LLC bought a new stake in Xenon Pharmaceuticals during the second quarter valued at $252,000. Finally, Deutsche Bank AG increased its stake in Xenon Pharmaceuticals by 39.6% during the fourth quarter. Deutsche Bank AG now owns 73,200 shares of the biopharmaceutical company’s stock valued at $461,000 after purchasing an additional 20,777 shares during the last quarter. Hedge funds and other institutional investors own 68.88% of the company’s stock.

Several analysts recently issued reports on the stock. BidaskClub cut shares of Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, June 11th. Zacks Investment Research raised shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $15.00.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P.

Recommended Story: Penny Stocks

Earnings History for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.